uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-20-566-7394
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.11 million
Profitability
Miscellaneous
Employees202
OptionableOptionable
Uniqure (NASDAQ:QURE) Frequently Asked Questions
What is Uniqure's stock symbol?
Uniqure trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure's earnings last quarter?
Uniqure NV (NASDAQ:QURE) posted its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.03. The biotechnology company earned $3.15 million during the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. View Uniqure's Earnings History.
When is Uniqure's next earnings date?
What price target have analysts set for QURE?
10 equities research analysts have issued 1-year price objectives for Uniqure's shares. Their predictions range from $30.00 to $76.00. On average, they anticipate Uniqure's share price to reach $57.6667 in the next year. This suggests a possible upside of 46.5% from the stock's current price. View Analyst Price Targets for Uniqure.
What is the consensus analysts' recommendation for Uniqure?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Uniqure.
What are Wall Street analysts saying about Uniqure stock?
Here are some recent quotes from research analysts about Uniqure stock:
- 1. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and are raising our 12-month price target to $68 from $65. This morning, uniQure announced and held a conference call to discuss additional results from the Phase 2b AMT-061 trial in severe hemophilia B. The announcement was simultaneous with an oral presentation at the Disorders (EAHAD) conference in Prague." (2/8/2019)
- 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (1/17/2019)
- 3. HC Wainwright analysts commented, "Our $60 price target vs. prior $48, is based on a 13-year DCF analysis that incorporates rNPV of two clinical-stage pipeline products AMT-061 and AMT-130. For AMT-061, we assume a 70% POS driven by the compelling clinical update, refer to our November 15, 2018 note for details, vs. 65% POS previously and anticipate commercial launch during 2H-2021, with a lower NAB-based exclusion of 5% vs. prior 10%, and model risk-adjusted peak sales of roughly $1.14B (vs. $981M previously), during 2028. We assume a launch price of $850K (vs." (11/26/2018)
- 4. Chardan Capital analysts commented, "We note organ-specific promoters will help mitigate toxicity issues associated with off-target expression of transgenes. In addition, better promoters means potentially lower dosage of vector genomes will be required to achieve therapeutic levels of therapeutic protein levels." (10/18/2018)
Has Uniqure been receiving favorable news coverage?
Media coverage about QURE stock has been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Uniqure earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Uniqure's key competitors?
Some companies that are related to Uniqure include Amarin (AMRN), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), Evotec (EVTCY), HUTCHISON CHINA/S (HCM) and Emergent Biosolutions (EBS).
Who are Uniqure's key executives?
Uniqure's management team includes the folowing people:
- Mr. Matthew Craig Kapusta, CEO, CFO & Exec. Director (Age 47)
- Dr. Sander Van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & Gen. Mang. of Amsterdam (Age 65)
- Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
- Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
- Dr. Scott T. McMillan, Chief Operating Officer (Age 60)
Who are Uniqure's major shareholders?
Uniqure's stock is owned by many different of retail and institutional investors. Top institutional investors include 683 Capital Management LLC (2.91%), BlackRock Inc. (1.26%), RTW Investments LP (1.24%), Sphera Funds Management LTD. (0.62%), Perceptive Advisors LLC (0.59%) and Lord Abbett & CO. LLC (0.41%). Company insiders that own Uniqure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Harald Petry, Jeremy P Springhorn, Maria E Cantor, Matthew C Kapusta, Philip Astley-Sparke, Scott T Mcmillan and Steven Zelenkofske. View Institutional Ownership Trends for Uniqure.
Which institutional investors are selling Uniqure stock?
QURE stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, WS Management Lllp, D. E. Shaw & Co. Inc., BlackRock Inc., Squarepoint Ops LLC, Bellevue Group AG, Two Sigma Advisers LP and Henry James International Management Inc.. Company insiders that have sold Uniqure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jeremy P Springhorn, Matthew C Kapusta, Philip Astley-Sparke, Scott T Mcmillan and Steven Zelenkofske. View Insider Buying and Selling for Uniqure.
Which institutional investors are buying Uniqure stock?
QURE stock was acquired by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Alps Advisors Inc., Sphera Funds Management LTD., RTW Investments LP, Geode Capital Management LLC, Bank of America Corp DE, Caption Management LLC and HRT Financial LLC. View Insider Buying and Selling for Uniqure.
How do I buy shares of Uniqure?
Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Uniqure's stock price today?
One share of QURE stock can currently be purchased for approximately $39.35.
How big of a company is Uniqure?
Uniqure has a market capitalization of $1.47 billion and generates $13.11 million in revenue each year. The biotechnology company earns $-79,260,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Uniqure employs 202 workers across the globe.
What is Uniqure's official website?
How can I contact Uniqure?
Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-566-7394 or via email at [email protected]
MarketBeat Community Rating for Uniqure (NASDAQ QURE)
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
